Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Sep:61:102769.
doi: 10.1016/j.ctim.2021.102769. Epub 2021 Aug 15.

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Abdulrahman E Koshak  1 , Emad A Koshak  2 , Abdullah F Mobeireek  3 , Mazen A Badawi  2 , Siraj O Wali  2 , Husam M Malibary  2 , Ali F Atwah  4 , Meshari M Alhamdan  5 , Reem A Almalki  2 , Tariq A Madani  2
Affiliations
Randomized Controlled Trial

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Abdulrahman E Koshak et al. Complement Ther Med. 2021 Sep.

Abstract

Background: Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recommended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19.

Methods: All adult patients with mild COVID-19 symptoms presented to King Abdulaziz University Hospital, Jeddah, Saudi Arabia, were recruited for an open label randomized clinical trial (RCT). They were randomly divided into control or treatment groups, with the latter receiving 500 mg NSO (MARNYS® Cuminmar) twice daily for 10 days. Symptoms were daily monitored via telecommunication. The primary outcome focused on the percentage of patients who recovered (symptom-free for 3 days) within 14-days. The trial was registered at clinicaltrials.gov (NCT04401202).

Results: A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53 % of patients were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered patients in NSO group (54[62 %]) was significantly higher than that in the control group (31[36 %]; p = 0.001). The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the control group (12.3 ± 2.8 days); p = 0.001.

Conclusions: NSO supplementation was associated with faster recovery of symptoms than usual care alone for patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with placebo-controlled, double-blinded studies.

Keywords: COVID-19; Herbal medicine; Nigella sativa; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors report no declarations of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of patient’s enrollment.
Fig. 2
Fig. 2
The number of patients who recovered within the study period.
See this image and copyright information in PMC

References

    1. World Health Organization . 2020. Timeline of WHO’s response to COVID-19.https://www.who.int/news-room/detail/29-06-2020-covidtimeline Published 2020. (Accessed 6 August 2020)
    1. Saudi Center for Disease Prevention and Control . 2020. Daily updates.https://covid19.cdc.gov.sa/daily-updates/
    1. Vijayvargiya P., Esquer Garrigos Z., Castillo Almeida N.E., Gurram P.R., Stevens R.W., Razonable R.R. Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof) Mayo Clin Proc. 2020;95(7):1454–1466. doi: 10.1016/j.mayocp.2020.04.027. - DOI - PMC - PubMed
    1. World Health Organization . 2020. Clinical management of COVID-19.https://www.who.int/publications/i/item/clinical-management-of-covid-19 Published 2020. (Accessed 27 August 2020)
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed

Publication types

Associated data